A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life

British Journal of Haematology

Volumn 120, Issue 6, 2003, Pages 1037-1046

  Hellström Lindberg, Eva ^a   Gulbrandsen, Nina ^b   Lindberg, Greger ^a   Ahlgren, Tomas ^c   Dahl, Inger Marie S ^d   Dybedal, Ingunn ^e   Grimfors, Gunnar ^a   Hesse Sundin, Eva ^a   Hjorth, Martin ^a   Kanter Lewensohn, Lena ^a   Linder, Olle ^a   Luthman, Michaela ^f   Löfvenberg, Eva ^f   Öberg, Gunnar ^f   Porwit MacDonald, Anja ^a   Rådlund, Anders ^f   Samuelsson, Jan ^g   Tangen, Jon Magnus ^b   Winquist, Ingemar ^h   Wisloff, Finn ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Depts Med/Haematol the Hospitals   (Sweden)

^d Depts Med/Haematol the Hospitals   (Norway)

^e Depts Med/Haematol the Hospitals   (Norway)

^f ST GÖRAN S HOSPITAL   (Sweden)

^g STOCKHOLM SÖDER HOSPITAL   (Sweden)

^h Southern Hospital   (Sweden)

Author keywords

Anaemia; Erythropoietin; Granulocyte colony stimulating factor; Myelodysplasia

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPNEA; EVALUATION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE;

EID: 0037353935     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04153.x     Document Type: Article

References (32)

1. Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B., de Haes, J.C., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P.B., Schraub, S., Sneeuw, K., Sullivan, M. & Takeda, F. (1993) The European Organization for Research and Treatment of Cancer QLQ C-30: a quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365-376.
2. Backx, B., Broeders, L. & Löwenberg, B. (1992) Kit ligand improves in vitro erythropoiesis in myelodysplastic syndromes. Blood, 80, 1213-1217.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., Sultan, C. & The French-American-British (FAB) Group (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
4. Casadevall, N., Durieux, P., Dubois, S., Lepage, E., Hemery, F., Quarre, M.C., Fenaux, P., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Stamatoullas, A., Vekhoff, A., Ribrag, V. & Dreyfus, F. pour le Groupe Francais des Myelodysplasies (2001) Erythropoietin (rHuEpo) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results of a randomized trial with impact on quality of life and costs. Blood, 98, 3522 (abstract).
5. Cheson, B., Bennett, J.M., Kantarijan, Pinto, A., Schiffer, C.A., Nimer, S.D., Löwenberg, B., Beral, M., de Witte, T., Stone, R., Mittelman, M., Sanz, G.F., Wijermans, P., Gore, S. & Greenberg, P. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 3671-3674.
6. Greenberg, P.L. (1994) The myelodysplastic syndromes. In: Haematology: Basic Principles and Practice, 2nd edn (ed. by R. Hoffman, E. Benz, S. Shattil, B. Furie & H. Cohen), pp. 1098-1121. Churchill Livingstone, New York.
7. Greenberg, P.L., Cox, C., LeBeau, M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
8. Hast, R., Wallvik, J., Folin, A., Bernell, P. & Stenke, L. (2001) Long-term follow-up of 18 patients with myelodysplastic syndromes with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leukemia Research, 25, 19-21.
9. Hellström-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes. An analysis of 205 patients in 17 studies. British Journal of Haematology, 89, 67-71.
10. Hellström-Lindberg, E., Kanter-Lewensohn, L. & Öst, Å. (1997a) Morphological changes and apoptosis in bone marrow from patients treated with granulocyte-CSF and erythropoietin. Leukemia Research, 21, 415-455.
11. Hellström-Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Öst, Å. & Greenberg, P. (1997b) Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology, 99, 344-351.
12. Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. & Öst, Å. (1998) Treatment of the anemia in myelodysplastic syndromes with granulocyte-CSF plus erythropoietin: results from a randomized phase II study and long-term follow-up on 71 patients. Blood, 92, 68-75.
13. Hellström-Lindberg, E., Willman, C., Barrett, A.J. & Saunthararajah, Y. (2000) Achievements in Understanding and Treatment of Myelodysplastic Syndromes. Haematology 2000, pp. 110-132. American Society of Haematology, Washington, DC.
14. Hilden, J., Habbema, J.D.F. & Bjerregaard, B. (1978) The measurement of performance in probabilistic diagnosis. II. Trustworthiness of the exact values of the diagnostic probabilities. Methods in Infectious Medicine, 17, 227-237.
15. Hjermstad, M.J., Fossa, S.D., Bjordal, K. & Kaasa, S. (1995) Test/retest study of the European Organization for Research and Treatment of Cancer core quality of life questionnaire. Journal of Clinical Oncology, 13, 1249-1254.
16. Hjermstad, M.J., Fayers, P.M., Bjordal, K. & Kaasa, S. (1998a) Health Related Quality of Life in the general population assessed by the EORTC Core Quality of Life Questionnaire - the EORTC QLQ-C30 (+3) Journal of Clinical Oncology, 16, 1188-1196.
17. Hjermstad, M.J., Fayers, P.M., Bjordal, K. & Kaasa, S. (1998b) Using reference data on quality of life - the importance of adjusting for age and sex, exemplified by the EORTC QLQ-C30 (+3). European Journal of Cancer, 34, 1381-1389.
18. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodyplastic syndromes. British Journal of Haematology, 103, 1070-1074.
19. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds) (2001). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. IARC Press, Lyon.
20. Kaasa, S., Bjordal, K., Aaronson, N., Moum, T., Wist, E., Hagen, S. & Kvikstad, A. (1995) The EORTC Core Quality of Life Questionnaire (QLQ C-30): validity and reliability when analyzed with patients treated with palliative radiotherapy. European Journal of Cancer. 31A, 2260-2263.
21. Kornblith, A.B., Herndon, I.I.J.E., Silverman, L.R., Demakos, E.P., Odchimar-Reissig, R., Holland, J.F., Powell, B.L., DeCastro, C., Ellerton, J., Larson, R.A., Schiffer, C. & Holland, J.C. (2002) Impact of azacytidine on the quality of life of patients with the myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia group B study. Journal of Clinical Oncology, 20, 2441-2452.
22. Mantovani, L., Lentini, G., Hentschel, B., Wickramanayake, P.D., Loeffler, M., Diehl, V. & Tesch, H. (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor. British Journal of Haematology, 109, 367-375.
23. Negrin, R.S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S. & Greenberg, P.L. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood, 87, 4076-4081.
24. Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. (1998) Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16, 139-144.
25. Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J.M., Marcus, B., Khan, Z., Chancy, C., Showel, J., Gregory, S. & Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268-276.
26. Remacha, A.F., Arrizabalaga, B., Villegas, A., Manteiga, R., Calvo, T., Julia, A., Fernandez Fuertes, I., Gonzalez, F.A., Font, L., Junca, J., del Arco, A., Malcorra, J.J., Equiza, E.P., de Mendiguren, B.P. & Romero, M. (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group, Haematologica, 84, 1058-1064.
27. Schmidt-Mende, J., Tehranchi, R., Forsblom, A.M., Joseph, B., Christensson, B., Fadeel, B., Zhivotovsky, B., Hellström-Lindberg, E. & Hellström-Lindberg, E. (2001) Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed side-roblasts. Leukemia, 15, 742-751.
28. Spiegelhalter, D.J. (1983) Evaluation of clinical decision-aids, with application to a system for dyspepsia. Statistics in Medicine, 2, 207-216.
29. Tehranchi, R., Fadeel, B., Forsblom, A.M., Christensson, B., Samuelsson, J., Zhivotovsky, B. & Hellstrom-Lindberg, E. (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood, 101, 1080-1086.
30. Thomas, M. (2001) Quality of life in myelodysplastic syndromes: Measurement issues in research and in clinical practice. Leukemia Research, Suppl. 1, Or28 (abstract).
31. Van de Loosdrecht, A.A. & Vellenga, E. (2000) Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis. Medical Oncology, 17, 573-578.
32. Wisloff, F., Hjorth, M., Kaasa, S. & Westin, J. (1996) Measurement of health-related quality of life in multiple myeloma. British Journal of Haematology, 92, 604-613.